Optimization of algorithms for in vivo preclinical screening of compounds with an alleged antitumor effect
- Authors: Dodokhova M.A.1, Voronova O.V.1,2, Alkhusein-Kulyaginova M.S.1, Gulyan M.V.1, Kotieva E.M.1, Korobka S.Y.1, Kotieva V.M.1, Karapetyan K.K.1, Vlasova N.D.1, Shpakovsky D.B.3, Milaeva E.R.3, Kotieva I.M.1
-
Affiliations:
- Rostov State Medical University
- Rostov-on-Don Clinical Hospital «Russian Railways-Medicine»
- Lomonosov Moscow State University
- Issue: Vol 28, No 2 (2023)
- Pages: 119-135
- Section: Original Study Articles
- URL: https://journals.rcsi.science/1028-9984/article/view/254437
- DOI: https://doi.org/10.17816/onco501804
- ID: 254437
Cite item
Abstract
BACKGROUND: Despite a large number of publications on preclinical studies of compounds with a suspected antitumor effect on in silico and in vitro models, in vivo studies are the most informative. The experimental part of the work on laboratory animals has its own peculiarities in the field of preclinical research: a large number of animals and analog compounds in the series, two- and three-phase staging, and, consequently, high cost and labor-intensive execution.
AIM: Optimization of algorithms for screening preclinical in vivo studies of compounds with a suspected antitumor effect.
MATERIALS AND METHODS: To form the algorithm in the preclinical study, primary data was obtained using standard pharmacological (determination of the toxicity class index, antitumor and antimetastatic activity, inhibition of tumor growth by weight, average life expectancy of animals) and morphological (autopsy, micropreparations with hematoxylin and eosin staining, as well as immunohistochemical study using monoclonal antibodies) methods with the selection of leading compounds for in-depth study with a description of the mechanism of pharmacological activity.
RESULTS: Based on a series of comparative experiments, the following algorithm of preclinical in vivo study for newly synthesized compounds with an alleged antitumor effect has been tested.
Stage 1. Determination of the toxicity class with a single intragastric administration to Wistar rats according to the Organization for Economic Co-operation and Development 420 protocol and selection of candidates for antitumor drugs according to the principle of the greatest safety of use.
Stage 2. Determination of the presence/absence of pharmacological activity of the tested compounds. Compounds of toxicity classes IV and V (according to the Globally Harmonized System of Hazard Classification and Labeling of Chemical Products) in a wide range of doses (doses are selected depending on the toxicity class) are examined for pharmacological activity before the natural death of tumor-bearing animals with the identification of leader substances, in-depth study of which is appropriate. The selection of promising substances and total doses for administration at the next stage is determined by the life expectancy of tumor-bearing animals.
Stage 3. Determination of indicators of antitumor and antimetastatic activity of leader substances with a fixed euthanasia period for all tumor-bearing animals and determination of possible mechanisms for the implementation of the therapeutic effect using immunohistochemical analysis.
Stage 4. To study the effect of the tested compounds on the growth rates of the primary tumor node and metastatic foci at different stages of the development of the tumor process, when administered in different modes, as part of combined and monochemotherapy, with mandatory clarification of the mechanisms for the implementation of antitumor and antimetastatic activity using biochemical and immunohistochemical techniques.
Stage 5. The study of the most promising compounds according to the guidelines for preclinical safety studies for the purpose of clinical trials and registration of medicines (the document was approved by the decision of the Board of the Eurasian Economic Commission of November 26, 2019, N 202): «Toxicity studies with repeated (multiple) administration of the drug, preclinical studies conducted in order to justify the conduct of exploratory clinical studies, studies of local tolerability of the drug, studies of genotoxicity of the drug, carcinogenicity of the drug, etc.»
CONCLUSIONS: The step-by-step exclusion of the tested compounds from the line of similarly-structured substances described by us will increase the efficiency of selecting promising candidates for antitumor drugs and reduce the cost of conducting preclinical studies of compounds with an alleged antitumor effect.
Full Text
##article.viewOnOriginalSite##About the authors
Margarita A. Dodokhova
Rostov State Medical University
Author for correspondence.
Email: dodohova@mail.ru
ORCID iD: 0000-0003-3104-827X
MD, Dr. Sci. (Med.)
Russian Federation, Rostov-on-DonOlga V. Voronova
Rostov State Medical University; Rostov-on-Don Clinical Hospital «Russian Railways-Medicine»
Email: 9043401873@mail.ru
ORCID iD: 0000-0003-0542-6900
Cand. Sci. (Med.)
Russian Federation, Rostov-on-Don; Rostov-on-DonMargarita S. Alkhusein-Kulyaginova
Rostov State Medical University
Email: rita.kuljaginva@rambler.ru
ORCID iD: 0000-0001-5123-5289
Russian Federation, Rostov-on-Don
Marina V. Gulyan
Rostov State Medical University
Email: 25marinablik@mail.ru
ORCID iD: 0000-0001-6023-8916
MD, Cand. Sci. (Med.), Assistant Professor
Russian Federation, Rostov-on-DonElizaveta M. Kotieva
Rostov State Medical University
Email: elizaveta.kotieva@mail.ru
ORCID iD: 0000-0002-5595-8799
Russian Federation, Rostov-on-Don
Svetlana Yu. Korobka
Rostov State Medical University
Email: Svetlana_ik85@mail.ru
ORCID iD: 0009-0006-3978-9979
Russian Federation, Rostov-on-Don
Violetta M. Kotieva
Rostov State Medical University
Email: violetta.kotieva@mail.ru
ORCID iD: 0000-0003-1783-1073
Russian Federation, Rostov-on-Don
Kristina K. Karapetyan
Rostov State Medical University
Email: aparvarvaravrar@gmail.com
ORCID iD: 0000-0003-1247-7933
Russian Federation, Rostov-on-Don
Nadezhda D. Vlasova
Rostov State Medical University
Email: nadezhda.vlas161@yandex.ru
Russian Federation, Rostov-on-Don
Dmitry B. Shpakovsky
Lomonosov Moscow State University
Email: dmshpak@mail.ru
ORCID iD: 0000-0002-7824-3382
Cand. Sci. (Chem.)
Russian Federation, MoscowElena R. Milaeva
Lomonosov Moscow State University
Email: helenamilaeva@mail.ru
ORCID iD: 0000-0002-5489-3866
Dr. Sci. (Chem.), Professor
Russian Federation, MoscowInga M. Kotieva
Rostov State Medical University
Email: kukulik70@mail.ru
ORCID iD: 0000-0002-2796-9466
MD, Dr. Sci. (Med.), Professor
Russian Federation, Rostov-on-DonReferences
- Upadhyay N, Tilekar K, Loiodice F, et al. Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy. Bioorganic Chemistry. 2021;107:104527. doi: 10.1016/j.bioorg.2020.104527
- Avxentyev NA, SisiginaNN, Frolov MYu, Makarov AS. Analysis of novel antineoplastic drugs treatment impact on the federal project «cancer control» goals achievement. Problems in oncology. 2021;67(6):768–776. (In Russ). doi: 10.37469/0507-3758-2021-67-6-768-776
- Abakumov GA, Piskunov AV, Cherkasov VK, et al. Organoelement chemistry: promising growth areas and challenges. Russian Chemical Reviews. 2018;87(5):393–507. (In Russ). doi: 10.1070/RCR4795
- Bührmann M, Kallepu S, Warmuth JD, et al. Fragtory: Pharmacophore-Focused Design, Synthesis, and Evaluation of an sp3-Enriched Fragment Library. Journal of Medicinal Chemistry. 2023;66(9):6297–6314. doi: 10.1021/acs.jmedchem.3c00187
- Vasiliev AN, Niyazov RR, Gavrishina EV, Dranytsina MA, Kulichev DA. Problems of planning and conduct of preclinical trials in the Russian Federation. Remedium. Journal about the Russian market of medicines and medical equipment. 2017;(9):6–19. (In Russ). doi: 10.21518/1561-5936-2017-9-6-18
- Nehra B, Mathew B, Chawla PA. A Medicinal Chemist’s Perspective Towards Structure Activity Relationship of Heterocycle Based Anticancer Agents. Current Topics in Medicinal Chemistry. 2022;22(6):493–528. doi: 10.2174/1568026622666220111142617
- Semin AA. The question of strengthening the research capacities in drug innovation. Remedium. Journal about the Russian market of medicines and medical equipment. 2018;(3):6–15. (In Russ). doi: 10.21518/1561-5936-2018-3-6-15
- Melezhnikova NO, Domnina AP, Goryachaya TS, Petrosyan MA. Kletochnye tekhnologii v farmakologicheskikh issledovaniyakh. nastoyashchee i budushchee. Tsitologiya. 2018;60(9):673–678. (In Russ). doi: 10.7868/s0041377118090023
- Bezborodova OA, Pankratov AA, Nemtsova ER, et al. Anti-Tumour Drugs: Planning Preclinical Efficacy and Safety Studies. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2020;10(2):96–110. (In Russ). doi: 10.30895/1991-2919-2020-10-2-96-110
- Shpakovsky DB, Banti CN, Mukhatova EM, et al. Synthesis, antiradical activity and in vitro cytotoxicity of novel organotin complexes based on 2,6-di-tert-butyl-4-mercaptophenol. Dalton Trans. 2014;43(18):6880–6890. doi: 10.1039/c3dt53469c
- Nikitin EA, Shpakovsky DB, Tyurin VYu, et al. Novel organotin complexes with phenol and imidazole moieties for optimized antitumor properties. Journal of Organometallic Chemistry. 2022;959:122212. doi: 10.1016/j.jorganchem.2021.122212
- OECD (2002), Test No. 420: Acute Oral Toxicity — Fixed Dose Procedure. OECD Guidelines for the Testing of Chemicals, Section 4. OECD Publishing, Paris. doi: 10.1787/9789264070943-en
- Avdeeva OI, Makarova MN, Kalatanova AV, Kovaleva MA. Bioethical And Economic Aspects In The Basis Of A Choice Of A Method Of Studying Of Toxicity Of Medical Products At Single Introduction. Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science). 2018;(1):4–11. (In Russ). doi: 10.29296/2618723X-2018-01-01
- Kotieva IM, Frantsiyants EM, Kaplieva IV, et al. Influence of chronic pain on some metabolic processes in the skin of female mice. Russian Journal of Pain. 2018;4(58):46–54. doi: 10.25731/RASP.2018.04.027
- Karkishchenko NN, Grachev SV, editors. Rukovodstvo po laboratornym zhivotnym i al’ternativnym modelyam v biomeditsinskikh tekhnologiyakh. Moscow: Profil’; 2010. (In Russ).
- Khabriev RU, editor. Rukovodstvo po eksperimental’nomu (doklinicheskomu) izucheniyu novykh farmakologicheskikh veshchestv. 2nd edition. Moscow: Meditsina; 2005. (In Russ).
- Ma W, Qin Y, Chapuy B, Lu Ch. LRRC33 is a novel binding and potential regulating protein of TGF-β1 function in human acute myeloid leukemia cells. PLoS One. 2019;14(10):e0213482. doi: 10.1371/journal.pone.0213482
- Wang J, Xiang H, Lu Y, Wu T. Role and clinical significance of TGF β1 and TGF βR1 in malignant tumors (Review). International Journal of Molecular Medicine. 2021;47(4). doi: 10.3892/ijmm.2021.4888
- de Stree G, Lucas S. Targeting immunosuppression by TGF-β1 for cancer immunotherapy. Biochemical Pharmacology. 2021;192:114697. doi: 10.1016/j.bcp.2021.114697
- Sato R, Imamura K, Semba T, et al. TGFβ Signaling Activated by Cancer-Associated Fibroblasts Determines the Histological Signature of Lung Adenocarcinoma. Cancer Research. 2021;81(18):4751–4765. doi: 10.1158/0008-5472.can-20-3941
- Melincovici CS, Boşca AB, Şuşman S, et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Romanian journal of morphology and embryology. 2018;59(2):455–467.
- Daneluzzi C, Seyed Jafari SM, Hunger R, Bossart S. The Immunohistochemical Assessment of Neoangiogenesis Factors in Squamous Cell Carcinomas and Their Precursors in the Skin. Journal of Clinical Medicine. 2022;11(15):4494. doi: 10.3390/jcm11154494
- Jiang X, Wang J, Deng X, et al. The role of microenvironment in tumor angiogenesis. Journal of Experimental & Clinical Cancer Research. 2020;39(1). doi: 10.1186/s13046-020-01709-5
- Adams JM, Cory S. The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death & Differentiation. 2018;25(1):27–36. doi: 10.1038/cdd.2017.161
- Suraweera CD, Banjara S, Hinds MG, Kvansakul M. Metazoans and Intrinsic Apoptosis: An Evolutionary Analysis of the Bcl-2 Family. International Journal of Molecular Sciences. 2022;23(7):3691. doi: 10.3390/ijms23073691
- Krishna S, Kumar SB, Krishna Murthy TP, Murahari M. Structure-based design approach of potential BCL-2 inhibitors for cancer chemotherapy. Computers in Biology and Medicine. 2021;134:104455. doi: 10.1016/j.compbiomed.2021.104455
- Vincek E, Rudnick E. Melanocytic marker Melan-A detects molluscum contagiosum bodies. Journal of Histotechnology. 2022;45(1):36–38. doi: 10.1080/01478885.2021.1964872
- Ronchi A, Zito Marino F, Toni G, et al. Diagnostic performance of melanocytic markers for immunocytochemical evaluation of lymph-node melanoma metastases on cytological samples. Journal of Clinical Pathology. 2022;75(1):45–49. doi: 10.1136/jclinpath-2020-206962
- Shamanova AYu, Kazachkov EL, Panova IE, Rostovtsev DM Prediktivnye aspekty prizhiznennogo patologoanatomicheskogo issledovaniya uveal’nykh melanom. Voprosy Onkologii. 2022;68(3 suppl.):132–133. (In Russ).
- Gushchina SV, Makarova MN, Pozharitskaya ON. Sravnitel’noe toksikologicheskoe izuchenie nositelei dlya lekarstvennykh sredstv, primenyaemykh v doklinicheskikh issledovaniyakh. International bulletin of Veterinary Medicine. 2015;(3):92–98. (In Russ).
- Kazancheva OD, Gerasimenko AS. Search methodology of the new biologically active pharmaceutical substances with receptor activity. International Journal of Applied and Fundamental Research. 2016;(8 Pt 4):522–525. (In Russ).
- Kirichenko DV. The effect of physic-chemical properties of the components of dosage forms on the selection of vehicle for the administration to laboratory animals. Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science). 2020;(2):76–81. (In Russ). doi: 10.29296/2618723X-2020-02-09
- Koptyaeva KE, Muzhikyan AA, Guschin YaA, et al. Technique Of Dissection And Extracting Organs Of Laboratory Animals. Message 1 (Rats). Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science). 2018;1(2):71–92. (In Russ). doi: 10.29296/2618723X-2018-02-08
- Koptyaeva KE, Muzhikyan AA, Guschin YaA, et al. Technique Of Dissection And Extracting Organs Of Laboratory Animals. Message 2: Mouse. Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science). 2018;1(4):50–73. (In Russ). doi: 10.29296/2618723X-2018-04-05
- Treshchalina EM, Zhukova OS, Gerasimova GK, Andronova NV, Garin AM. Metodicheskie rekomendatsii po doklinicheskomu izucheniyu protivoopukholevoi aktivnosti lekarstvennykh sredstv. In: Nauchnyi tsentr ekspertizy sredstv meditsinskogo primeneniya Minzdravsotsrazvitiya Rossii. Chast’ 1. Moscow: Grif i K; 2012. P. 642–657. (In Russ).
- Kiseleva MP, Pokrovsky VS, Borisova LM, Golubeva IS, Ektova LV. N-glycosidesindolo[2,3,-a]pyrrolo[3,4,-c]carbazole derivatives chemical structure influence on antitumor activity. Russian Journal of Biotherapy. 2019;18(2):32–39. (In Russ). doi: 10.17650/1726-9784-2019-18-2-32-39
- Abo Qoura L, Morozova EA, Koval VS, et al. Cytotoxic and antitumor properties of methionine γ-lyase conjugate in combination with S-alk(en)yl–L-cysteine sulfoxides. Russian Journal of Biotherapy. 2022;21(4):62–70. (In Russ). doi: 10.17650/1726-9784-2022-21-4-62-70
- Sof’ina ZP, Syrkin AB, Goldin AA, et al. Experimental evaluation of antitumor drugs in the USA and USSR and clinical correlations. Moscow: Meditsina; 1980. (In Russ).
- Kit OI, Kotieva IM, Frantsiyants EM, et al. Neurotransmitter systems of female mouse brain during growth of malignant melanoma modeled on the background of chronic pain. Pathogenesis. 2017;15(4):49–55. doi: 10.25557/GM.2018.4.9749
- Kit OI, Kotieva IM, Frantsiyants EM, et al. Angiogenesis growth factors in the intact and pathologically changed skin of female mice with malignant melanoma, which develops on the background of chronic pain. Russian Journal of Pain. 2017;3-4(54):17–25. (In Russ).